
The results of the landmark Phase III Lp(a)HORIZON clinical trial were presented on 7 November 2026 at the American Heart Association (AHA) Scientific Sessions and simultaneously published in the New England Journal of Medicine (NEJM). The trial investigated whether a new experimental medicine, pelacarsen, could reduce the risk of cardiovascular events, such as heart attacks and strokes, in people with elevated lipoprotein(a), or Lp(a), who already had cardiovascular disease. The results showed that although pelacarsen substantially lowered Lp(a) levels, it did not reduce the risk of major cardiovascular events (MACE) compared with placebo (an inactive treatment).
On 4 September 2026, Novartis announced that the Phase III Lp(a)HORIZON trial had not met its primary cardiovascular endpoint, despite substantially lowering Lp(a) levels. On 7 September, the Lp(a) International Task Force (ITF) issued an independent statement, emphasising the importance of awaiting the complete scientific results, including individual cardiovascular outcomes and subgroup analyses, before drawing definitive conclusions. On 16 October, Novartis informed patient organisations of its decision to discontinue the pelacarsen clinical development programme for atherosclerotic cardiovascular disease. FH Europe Foundation shared the company's official communication with the wider community, following a dedicated online discussion with Lp(a) Ambassadors, Patient Council representatives, clinical trial participants, joined by Prof. Florian Kronenberg, Chair of the Lp(a) International Task Force. With the detailed results now presented at AHA 2026 and published in peer-reviewed scientific journals, FHEF wishes to provide this accessible summary of the trial findings, including cardiovascular outcomes, subgroup results and reported side effects.
Lp(a)HORIZON was a large international clinical trial sponsored by Novartis, involving 8,323 participants across 797 clinical sites in 42 countries. All participants had elevated Lp(a) levels of at least 70 mg/dL and established cardiovascular disease, meaning they had previously experienced a heart attack, ischaemic stroke or symptomatic peripheral artery disease. Participants were aged 18–80 years, with an average age of approximately 60 years. Around 27% were women. Participants were randomly assigned to receive either:
The study followed participants for a median of 4.7 years. The primary objective was to determine whether lowering Lp(a) with pelacarsen could prevent further major cardiovascular events, including cardiovascular death, non-fatal heart attack, non-fatal stroke or an urgent procedure to restore blood flow to the heart.
Importantly, participants were already receiving treatment to reduce their cardiovascular risk, including cholesterol-lowering medicines and other recommended therapies. The trial investigated whether adding pelacarsen to their existing treatment could provide further protection against cardiovascular events.
Elevated Lp(a) is a recognised, genetically determined cardiovascular risk factor. The Lp(a)HORIZON trial specifically investigated whether lowering Lp(a) with pelacarsen could reduce further cardiovascular events in people who already had cardiovascular disease.
The difference between the two groups was not statistically significant.
The trial also assessed the safety and tolerability of pelacarsen. Several adverse events were reported more frequently among participants receiving pelacarsen than those receiving placebo.
| Reported adverse event or reaction | Pelacarsen | Placebo |
| Injection-site reactions | 25.6% | 2.9% |
| Flu-like symptoms and general reactions | 31.9% | 5.8% |
| Hypersensitivity reactions reported by investigators | 17.1% | 5.4% |
| Adverse event suspected to be related to pelacarsen or placebo | 56.8% | 18.0% |
| Adverse events leading to treatment discontinuation | 20.6% | 7.5% |
| Serious adverse events from any cause | 37.3% | 41.1% |
| Serious adverse event suspected to be related to pelacarsen or placebo | 1.9% | 0.2% |
Researchers also reported 19 cases of confirmed or probable anaphylaxis (0.5%) among participants receiving pelacarsen, compared with none in the placebo group. Anaphylaxis is a potentially life-threatening allergic reaction requiring urgent medical attention. Eight participants receiving pelacarsen were hospitalised following allergic reactions. No deaths from these reactions were reported. Following a suspected anaphylactic reaction during the trial in 2023, additional safety precautions were temporarily introduced, requiring injections to be administered under medical supervision. Adverse event suspected to be related to pelacarsen or placebo were 3 times higher in the pelacarsen group when compared to placebo (56.8% versus 18.0%). Overall, serious adverse events from any cause were reported in 37.3% of participants receiving pelacarsen and 41.1% receiving placebo, but 1.9% and 0.2% were suspected to be related to pelacarsen or placebo, respectively.
In clinical trials, a serious adverse event is a medical occurrence that meets specific criteria, such as requiring hospitalisation or being life-threatening. It does not necessarily mean that the event was caused by the medicine being studied. The findings also showed that adverse events suspected to be related to treatment were reported more frequently in the pelacarsen group than in the placebo group (56.8% versus 18.0%). Treatment discontinuation due to adverse events was also more common among participants receiving pelacarsen (20.6% versus 7.5%). These findings provide important information about the safety and tolerability of pelacarsen. Whether other Lp(a)-lowering medicines currently being investigated will demonstrate different cardiovascular outcomes remains to be established through ongoing clinical trials.
Importantly, the Lp(a)HORIZON findings do not change existing recommendations for Lp(a) testing, cardiovascular risk assessment and prevention. Elevated Lp(a) remains a recognised, genetically determined cardiovascular risk factor. As outlined in the European Atherosclerosis Society (EAS) consensus statement, measuring Lp(a) at least once in adulthood remains an important part of cardiovascular risk assessment.
Knowing a person's Lp(a) level helps healthcare professionals better understand their overall cardiovascular risk and guide the intensity of preventive measures, including the management of other risk factors such as LDL cholesterol, blood pressure, diabetes and smoking. The Lp(a)HORIZON findings do not call these recommendations into question. Rather, they highlight that we still need evidence from ongoing clinical trials to determine whether medicines specifically designed to lower Lp(a) can also reduce cardiovascular events.
For people living with elevated Lp(a), the message remains clear: knowing your Lp(a) level matters, and managing your overall cardiovascular risk remains essential. The results of one trial should not discourage people from getting tested or discussing appropriate preventive care with their healthcare professionals.
FH Europe Foundation acknowledges the invaluable contribution of the thousands of trial participants, their families, clinical teams and researchers whose commitment made this important international study possible.
Building on our earlier engagement with Lp(a) Ambassadors, Patient Council representatives and clinical trial participants, FHEF remains committed to providing clear, accessible and independent information, facilitating dialogue with scientific experts, and ensuring that the voices and experiences of people living with elevated Lp(a) continue to inform discussions about cardiovascular prevention and future research.
Looking ahead, FHEF is planning a dedicated community session in January 2027, bringing together people living with elevated Lp(a), clinical trial participants and scientific experts to discuss the Lp(a)HORIZON findings, address questions and provide further explanations in accessible language. Additional information will be shared through FHEF's communication channels.
Alongside the main results, researchers published further analyses in NEJM Evidence on 7 November 2026. These examined whether the findings differed according to treatment duration, uninterrupted treatment, the extent of Lp(a) reduction, participants' initial cardiovascular risk, or the number of cardiovascular events experienced. These additional analyses also found no evidence of a reduction in major cardiovascular events with pelacarsen.
The full results are available in two peer-reviewed scientific publications:
For those wishing to learn more about the scientific context and the questions arising from the Lp(a)HORIZON results, we also invite readers to explore:
Prepared by FH Europe Foundation in collaboration with Prof. Florian Kronenberg